BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
  • Homepage
  • Online Submission
Number of total visits
1254707
Number of visits today
445
Number of downloads
828498
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Wang X, Harrison JS, Studzinski GP. BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents. J Steroid Biochem Mol Biol 2017;173:139-47. [PMID: 27637326 DOI: 10.1016/j.jsbmb.2016.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, Beute WK, Harrison JS, Studzinski GP. JNK1 as a signaling node in VDR-BRAF induction of cell death in AML. J Steroid Biochem Mol Biol 2018;177:149-54. [PMID: 28765039 DOI: 10.1016/j.jsbmb.2017.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
2 Fearfield L, Nobbs J, Petruckevitch A, Harland C. Severe vitamin D deficiency associated with BRAF-mutated melanoma. Br J Dermatol 2019;181:1343. [PMID: 31381132 DOI: 10.1111/bjd.18413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Wang X, Nachliely M, Harrison JS, Danilenko M, Studzinski GP. Participation of vitamin D-upregulated protein 1 (TXNIP)-ASK1-JNK1 signalosome in the enhancement of AML cell death by a post-cytotoxic differentiation regimen. J Steroid Biochem Mol Biol 2019;187:166-73. [PMID: 30508644 DOI: 10.1016/j.jsbmb.2018.11.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Story MJ. Zinc, ω-3 polyunsaturated fatty acids and vitamin D: An essential combination for prevention and treatment of cancers. Biochimie 2021;181:100-22. [PMID: 33307154 DOI: 10.1016/j.biochi.2020.11.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Suzuki R, Kitamura Y, Nakamura Y, Akashi H, Ogawa Y, Kawada H, Ando K. Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma. Oncotarget 2020;11:3984-97. [PMID: 33216827 DOI: 10.18632/oncotarget.27775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345